MX2023006591A - Composiciones y metodos para el tratamiento de enfermedades oculares. - Google Patents

Composiciones y metodos para el tratamiento de enfermedades oculares.

Info

Publication number
MX2023006591A
MX2023006591A MX2023006591A MX2023006591A MX2023006591A MX 2023006591 A MX2023006591 A MX 2023006591A MX 2023006591 A MX2023006591 A MX 2023006591A MX 2023006591 A MX2023006591 A MX 2023006591A MX 2023006591 A MX2023006591 A MX 2023006591A
Authority
MX
Mexico
Prior art keywords
compositions
methods
treatment
eye diseases
age
Prior art date
Application number
MX2023006591A
Other languages
English (en)
Spanish (es)
Inventor
Ted Yednock
Anita Grover
Lori Taylor
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of MX2023006591A publication Critical patent/MX2023006591A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2023006591A 2020-12-04 2021-12-03 Composiciones y metodos para el tratamiento de enfermedades oculares. MX2023006591A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063121629P 2020-12-04 2020-12-04
PCT/US2021/061755 WO2022120137A1 (en) 2020-12-04 2021-12-03 Compositions and methods for treating ocular diseases

Publications (1)

Publication Number Publication Date
MX2023006591A true MX2023006591A (es) 2023-08-11

Family

ID=81853584

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006591A MX2023006591A (es) 2020-12-04 2021-12-03 Composiciones y metodos para el tratamiento de enfermedades oculares.

Country Status (11)

Country Link
US (1) US20240059765A1 (cg-RX-API-DMAC10.html)
EP (1) EP4255485A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023551734A (cg-RX-API-DMAC10.html)
KR (1) KR20230117192A (cg-RX-API-DMAC10.html)
CN (1) CN116782940A (cg-RX-API-DMAC10.html)
AU (1) AU2021391800A1 (cg-RX-API-DMAC10.html)
CA (1) CA3200976A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023001596A1 (cg-RX-API-DMAC10.html)
IL (1) IL303289A (cg-RX-API-DMAC10.html)
MX (1) MX2023006591A (cg-RX-API-DMAC10.html)
WO (1) WO2022120137A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510316UA (en) 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
FI3380518T3 (fi) 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
US12486322B2 (en) 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof
US20250313614A1 (en) * 2022-04-29 2025-10-09 Annexon, Inc. Compositions and methods for treating ocular diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510316UA (en) * 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
FI3380518T3 (fi) * 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä

Also Published As

Publication number Publication date
JP2023551734A (ja) 2023-12-12
CL2023001596A1 (es) 2024-01-19
AU2021391800A1 (en) 2023-06-22
US20240059765A1 (en) 2024-02-22
CN116782940A (zh) 2023-09-19
WO2022120137A1 (en) 2022-06-09
KR20230117192A (ko) 2023-08-07
EP4255485A1 (en) 2023-10-11
CA3200976A1 (en) 2022-06-09
IL303289A (en) 2023-07-01
EP4255485A4 (en) 2025-05-14

Similar Documents

Publication Publication Date Title
CL2023001596A1 (es) Composiciones y métodos para el tratamiento de enfermedades oculares
AR052172A1 (es) Inhibicion por arni de ctgf pra el tratamiento de trastornos oculares
CO2020014563A2 (es) Uso de clorhidrato de pilocarpina para el tratamiento de condiciones oculares
CO2023005996A2 (es) Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
IL286427B2 (en) Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
CR10041A (es) Uso de vías inhibitorias coplementarias para el tratamiento de enfermedades oculares
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
MX2021005518A (es) Modelos animales, métodos de detección y métodos de tratamiento para enfermedades o trastornos intraoculares.
MX2020010968A (es) Formulaciones de bevacizumab tamponadas para usarse en el tratamiento de enfermedades.
ZA202309651B (en) Compositions and methods for treatment of ocular disease associated with angiogenesis
AR062395A1 (es) Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares
BR112022005678A2 (pt) Métodos e composições para o tratamento da retinopatia diabética
MX2024013187A (es) Anticuerpos biespecíficos y métodos de tratamiento de las enfermedades oculares
MX2021008821A (es) Derivados de bis (diazirina) como foto-reticulante para el tratamiento de trastornos ectasicos de cornea.
JOP20230133A1 (ar) استخدام منشطات sGC لمعالجة الأمراض العينية
EA201990752A1 (ru) Офтальмологический состав, содержащий цитиколин, переносимый липосомой, для лечения глаукомы
PE20220384A1 (es) Composiciones y metodos de oximetazolina para el tratamiento de trastornos oculares
CL2024002758A1 (es) Agentes de interferencia de arn de sarm1
MX2022011234A (es) Composiciones y métodos para la salud ocular que comprenden ácidos grasos de cadena muy larga.
BR112022003759A2 (pt) Método e uso de pnpp-19 para prevenção e tratamento de doenças oculares
PE20240228A1 (es) Gotas para los ojos para tratar el adelgazamiento de la esclerotica y metodo de cribado para el agente terapeutico del adelgazamiento de la esclerotica
JPWO2019181967A1 (ja) 非侵襲的角膜又は強膜強化装置
BR112022018113A2 (pt) Composições e métodos para saúde ocular compreendendo areds e complexo de vitamina b
CL2024003281A1 (es) Anticuerpos específicos contra la proteína 7 relacionada con la angiopoyetina y usos de estos
BRPI0517972A (pt) ácido 5,6,7-triidroxiheptanóico e análogos para o tratamento de doenças oculares e doenças associadas com respostas hiperproliferativas e angiogênicas